Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases – Maximizing Success

2005 ◽  
Vol 136 (3) ◽  
pp. 217-229 ◽  
Author(s):  
Anne Durandy ◽  
Volker Wahn ◽  
Steve Petteway ◽  
Erwin W. Gelfand
2016 ◽  
Vol 7 (1) ◽  
pp. 30-36 ◽  
Author(s):  
Jarrett E. Walsh ◽  
Jose G. Gurrola ◽  
Scott M. Graham ◽  
Sarah L. Mott ◽  
Zuhair K Ballas

Author(s):  
Bas M. Smits ◽  
Ilona Kleine Budde ◽  
Esther de Vries ◽  
Ineke J. M. ten Berge ◽  
Robbert G. M. Bredius ◽  
...  

Abstract Background Patients with an IgG subclass deficiency (IgSD) ± specific polysaccharide antibody deficiency (SPAD) often present with recurrent infections. Previous retrospective studies have shown that prophylactic antibiotics (PA) and immunoglobulin replacement therapy (IRT) can both be effective in preventing these infections; however, this has not been confirmed in a prospective study. Objective To compare the efficacy of PA and IRT in a randomized crossover trial. Methods A total of 64 patients (55 adults and 9 children) were randomized (2:2) between two treatment arms. Treatment arm A began with 12 months of PA, and treatment arm B began with 12 months of IRT. After a 3-month bridging period with cotrimoxazole, the treatment was switched to 12 months of IRT and PA, respectively. The efficacy (measured by the incidence of infections) and proportion of related adverse events in the two arms were compared. Results The overall efficacy of the two regimens did not differ (p = 0.58, two-sided Wilcoxon signed-rank test). A smaller proportion of patients suffered a related adverse event while using PA (26.8% vs. 60.3%, p < 0.0003, chi-squared test). Patients with persistent infections while using PA suffered fewer infections per year after switching to IRT (2.63 vs. 0.64, p < 0.01). Conclusion We found comparable efficacy of IRT and PA in patients with IgSD ± SPAD. Patients with persistent infections during treatment with PA had less infections after switching to IRT. Clinical Implication Given the costs and associated side-effects of IRT, it should be reserved for patients with persistent infections despite treatment with PA.


2017 ◽  
Vol 52 ◽  
pp. 136-142 ◽  
Author(s):  
Antonio Pecoraro ◽  
Ludovica Crescenzi ◽  
Francescopaolo Granata ◽  
Arturo Genovese ◽  
Giuseppe Spadaro

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0223861
Author(s):  
Tri Dinh ◽  
Jun Oh ◽  
Donald William Cameron ◽  
Seung-Hwan Lee ◽  
Juthaporn Cowan

2008 ◽  
Vol 122 (4) ◽  
pp. 409-413 ◽  
Author(s):  
A Aghamohammadi ◽  
K Moazzami ◽  
N Rezaei ◽  
A Karimi ◽  
M Movahedi ◽  
...  

AbstractObjective:One hundred and nine patients with primary antibody deficiencies were selected in order to determine the frequency of ENT complications.Method:Demographic information and ENT medical histories were collected for each patient. Duration of study for each patient was divided into two periods of before diagnosis and after diagnosis and the initiation of treatment.Results:Eighty-two of 109 patients (75.2 per cent) experienced ENT infections during the course of the disease (63: otitis media, 75: sinusitis and nine: mastoiditis). At the time of diagnosis, 52 (47.7 per cent) out of 109 patients presented with an ENT symptom. The frequencies of episodes were 27 for sinusitis and 25 for otitis media (one complicated with mastoiditis). After immunoglobulin replacement therapy the incidence of otitis media was reduced from 1.75 before treatment to 0.39 after treatment per patient per year (p = 0.008). The incidence of sinusitis also significantly decreased from 2.38 to 0.78 (p value = 0.011).Conclusion:ENT infections are common medical problems in primary antibody deficiency patients. Persistent and recurrent ENT infections should be suspected as originating from a possible underlying immunodeficiency.


Sign in / Sign up

Export Citation Format

Share Document